Hope for kids with batten disease: new drug trial launches
Disease control
Not yet recruiting
This study tests an experimental drug called PLX-200 in children aged 6 to 18 with mild-to-moderate CLN3 disease (a form of Batten disease). The goal is to see if the drug can slow down the disease and is safe. About 39 participants will receive either PLX-200 or a placebo, and r…
Phase: PHASE3 • Sponsor: Polaryx Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 11:37 UTC